Stock Analysis
Addex Therapeutics (VTX:ADXN) Full Year 2023 Results
Key Financial Results
- Revenue: CHF1.65m (up 14% from FY 2022).
- Net loss: CHF10.6m (loss narrowed by 49% from FY 2022).
- CHF0.14 loss per share (improved from CHF0.46 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Addex Therapeutics Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 50%. Earnings per share (EPS) also surpassed analyst estimates by 18%.
Looking ahead, revenue is forecast to grow 89% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe.
Performance of the market in Switzerland.
The company's shares are down 18% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 6 warning signs for Addex Therapeutics (3 shouldn't be ignored!) that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Addex Therapeutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SWX:ADXN
Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
Flawless balance sheet and good value.